---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-146073"
form_type: "8-K"
ticker: "NUVB"
cik: "0001811063"
company_name: "Nuvation Bio Inc."
filed_at: "2023-05-16T23:59:59+00:00"
generated_at: "2026-06-14T23:56:36.071877+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Nuvation Bio annual meeting: directors elected, KPMG ratified, 20% opposed exec pay

## Summary
- Director Robert B. Bazemore Jr. re-elected with 140.6M for, 50.1M withheld (26% of votes cast).
- Kim Blickenstaff re-elected as Class B director with 1M for, none withheld.
- KPMG LLP ratified as auditor for FY2023 with 206.3M for, 0.1M against, 0.3M abstain.
- Advisory vote on executive compensation passed 153.7M for, 38.0M against (20% disapproval).
- Total shares represented 94% of Class A and 100% of Class B common stock.

## SEC filing metadata
- accession: 0001193125-23-146073
- form_type: 8-K
- ticker: NUVB
- cik: 0001811063
- company_name: Nuvation Bio Inc.
- filed_at: 2023-05-16T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811063/000119312523146073/0001193125-23-146073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811063/000119312523146073/d420969d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-146073
- JSON: https://secwatch.observer/filing/0001193125-23-146073.json
- Plain text: https://secwatch.observer/filing/0001193125-23-146073.txt

## Key facts
- Shareholder Votes
  Nuvation Bio Inc. shareholders approved Advisory vote on executive compensation at the 2023-05-15 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-05-15
  source text: Proposal No. 3 – To approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. FOR AGAINST ABSTAIN BROKER NON-VOTE 153,714,329 38,025,124 9,887 14,982,485
  evidence_url: https://www.sec.gov/Archives/edgar/data/1811063/000119312523146073/0001193125-23-146073-index.htm
- Shareholder Votes
  Nuvation Bio Inc. shareholders approved Ratification of Independent Registered Public Accounting Firm at the 2023-05-15 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-05-15
  source text: The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. FOR AGAINST ABSTAIN BROKER NON-VOTE 206,334,068 118,931 278,826 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1811063/000119312523146073/0001193125-23-146073-index.htm
- Shareholder Votes
  Nuvation Bio Inc. shareholders approved Election of Directors at the 2023-05-15 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-05-15
  source text: The individuals listed below were elected at the Annual Meeting to serve as directors of the Company until the Company’s 2026 annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal. CLASS A STOCK DIRECTORS: FOR WITHHELD BROKER NON-VOTE Mr. Robert B. Bazemore, Jr. 140,642,378 50,106,962 14,982,485 CLASS B STOCK DIRECTORS: FOR WITHHELD BROKER NON-VOTE Kim Blickenstaff 1,000,000 0 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1811063/000119312523146073/0001193125-23-146073-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.